Wearable, smartphone-controlled, rechargeable device effective for reducing voiding frequency; is safe in overactive bladder<\/p>\n<\/h3>\n
By Elana Gotkine HealthDay Reporter<\/b><\/p>\n
<\/b><\/p>\n
TUESDAY, April 2, 2024 (HealthDay News) — For patients with overactive bladder (OAB) symptoms, a wearable, smartphone-controlled, rechargeable transcutaneous tibial nerve stimulation (TTNS) device is efficacious and safe, according to a study published online March 11 in BJU International<\/em>.<\/p>\n Limin Liao, M.D., Ph.D., from the China Rehabilitation Science Institute in Beijing, and colleagues conducted a prospective, randomized clinical trial involving eligible patients with OAB symptoms who were randomly assigned to a TTNS or sham group.<\/p>\n The researchers found that the mean change of voiding frequency\/24 hours at four weeks was \u00e2\u0088\u00923.5 and \u00e2\u0088\u00920.6 in the stimulation and sham groups, respectively, in the full analysis set. The results were similar in the per-protocol set (\u00e2\u0088\u00923.5 versus \u00e2\u0088\u00920.4, respectively). Micturition volume\/void significantly improved at four weeks in both the full analysis set and per-protocol set. The improvement in patient perception of bladder condition was almost significant in the full analysis set and was significant in the per-protocol set. The American Urological Association Symptom Index Quality of Life Score improved significantly in both groups in the full analysis and per-protocol sets; no significant differences were seen in urgency score\/void, nocturia episodes\/day, or overactive bladder symptom score. There were no reports of device-related serious adverse events.<\/p>\n “TTNS using the novel, wearable, smartphone-controlled, rechargeable, and ambulatory TTNS device is effective and safe for treating OAB,” the authors write. “This approach could be a new potential home-based treatment modality.”<\/p>\n Abstract\/Full Text (subscription or payment may be required)<\/a><\/p>\n <\/i><\/p>\n